The article reviews the best and worst drug names for this year, as selected by the authors of The Readout newsletter[1]. It gives specific examples of names considered both good and inappropriate (specific names are given in the article)[1]. The text explains the criteria by which the names were evaluated, including memorability, clarity for physicians and patients, and risk of confusion with other drugs[1]. The article also provides background on the trade name registry and the industry name approval process[1]. There are additional biotechnology news items in The Readout newsletter, which the article briefly summarises, along with a ranking of names[1]. The article does not represent a new clinical trial or treatment outcome; it is an editorial assessment of names and accompanying biotechnology news[1].